Impel Neuropharma Inc (IMPLQ)
| Market Cap | 5.76M |
| Revenue (ttm) | 20.99M |
| Net Income (ttm) | -74.28M |
| Shares Out | 23.75M |
| EPS (ttm) | -3.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,240 |
| Open | 0.106 |
| Previous Close | n/a |
| Day's Range | 0.100 - 0.150 |
| 52-Week Range | n/a |
| Beta | 1.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About IMPLQ
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle,... [Read more]
Financial Performance
In 2022, IMPLQ's revenue was $12.65 million, an increase of 1794.01% compared to the previous year's $668,000. Losses were -$106.31 million, 38.7% more than in 2021.
Financial StatementsNews
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE , Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals I...
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Real-World Assessment Suggests that Concomitant Preventive and Acute Medication Use Decreases in Patients Using Trudhesa
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs.
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases wi...
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with ...
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases ...
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases ...
Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases w...
Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® TRx's Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million
Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference
SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases w...
Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)
CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases w...
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases wi...
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases wi...
Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation
Impel Celebrates Its One-Year Anniversary as a Public Company Today at the Nasdaq Stock Market Closing Bell Ceremony Starting at 3:45 p.m. EDT Impel Celebrates Its One-Year Anniversary as a Public Com...
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high...
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology
New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment
Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high...